Table 1. Baseline patients’ characteristics.
Characteristics | Population (N=40) |
---|---|
Age (years) | 63 [25–75] |
Male | 21 (53) |
Diagnosis | |
AML | 39 (98) |
Secondary AML | 12 (31) |
HRMDS | 1 (2) |
Prior regimens | 2 [1–6] |
Int/High dose cytarabine-based | 28 (70) |
HMA | 23 (58) |
Clofarabine-based | 11 (28) |
Salvage | |
1 | 14 (35) |
2 | 14 (35) |
≥3 | 12 (30) |
Duration of first remission (when achieved) (months) | 11 [1–52] |
Duration of remission on therapy received closest to clinical trial (months) | 4.3 [1–21] |
Prior SCT | 9 (23) |
WBC(x106 /L) | 1.8 [0.4–56] |
Hemoglobin (g/dL) | 9.5 [7.2–14.7] |
Platelets (x109/L) | 27 [2–231] |
Bone marrow blasts (%) | 34 [3–95] |
Peripheral blood blasts (%) | 11 [0–90] |
Cytogenetics | |
Diploid | 17 (43) |
Complex | 16 (40) |
−5/5q- and/or −7/7q- | 13 (33) |
Miscellaneous | 7 (17) |
IDH1/2 mutations | 7/37 (19) |
RUNX1 mutation | 6/37 (16) |
NRAS mutation | 5/39 (13) |
TP53 mutation | 4/37 (11) |
FLT3 mutation | 3/39 (8) |
NPM1 mutation | 3/38 (8) |
TET2 mutation | 2/37 (5) |
ASXL1 mutation | 2/37 (5) |
AML: acute myeloid leukemia; HRMDS: high-risk myelodysplastic syndrome; Int: Intermediate; HMA: hypomethylating agents; SCT: stem cell transplantation; WBC: white blood cell count.